VERU - Veru Inc Stock Price, Fair Value and News

1.33USD+0.06 (+4.72%)Market Closed

Market Summary

USD1.33+0.06

Market Closed

4.72%

VERU Stock Price

View Fullscreen

VERU RSI Chart

VERU Valuation

Market Cap

185.9M

Price/Earnings (Trailing)

-2.88

Price/Sales (Trailing)

11.67

EV/EBITDA

-2.98

Price/Free Cashflow

-3.12

VERU Price/Sales (Trailing)

VERU Profitability

EBT Margin

-402.05%

Return on Equity

-125.04%

Return on Assets

-80.09%

Free Cashflow Yield

-32.01%

VERU Fundamentals

VERU Revenue

Revenue (TTM)

15.9M

Rev. Growth (Yr)

-14.64%

Rev. Growth (Qtr)

-44.57%

VERU Earnings

Earnings (TTM)

-64.5M

Earnings Growth (Yr)

77.54%

Earnings Growth (Qtr)

23.33%

Breaking Down VERU Revenue

Last 7 days

1.6%

Last 30 days

126.8%

Last 90 days

195.4%

Trailing 12 Months

-9.3%

How does VERU drawdown profile look like?

VERU Financial Health

Current Ratio

3.21

Debt/Equity

0.03

Debt/Cashflow

-34.95

VERU Investor Care

Dividend Yield

16.03%

Dividend/Share (TTM)

0.21

Shares Dilution (1Y)

77.27%

Diluted EPS (TTM)

-0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	21.3M	15.0M	16.3M	15.9M
2022	60.5M	52.4M	39.4M	27.7M
2021	50.0M	57.4M	61.3M	60.8M
2020	39.0M	39.6M	42.6M	46.6M
2019	24.1M	28.3M	31.8M	36.0M
2018	13.2M	14.4M	15.9M	19.6M
2017	14.8M	13.5M	13.7M	13.0M
2016	28.0M	25.7M	22.1M	17.1M
2015	31.1M	31.0M	32.6M	34.2M
2014	23.1M	23.7M	24.5M	24.5M
2013	38.0M	36.6M	31.5M	28.2M
2012	27.1M	32.2M	35.0M	36.3M
2011	20.4M	19.5M	18.6M	23.5M
2010	0	24.9M	22.2M	21.3M
2009	0	0	27.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Veru Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 15, 2022	eisenberger mario	acquired	156,950	1.5695	100,000	-
Aug 15, 2022	eisenberger mario	sold	-2,003,550	20.0355	-100,000	-
Aug 17, 2021	lu lucy	bought	32,542	6.7796	4,800	-
Jun 16, 2021	fisch harry	sold	-835,300	8.353	-100,000	-
Mar 10, 2021	hyun grace	bought	49,315	14.09	3,500	-
Feb 12, 2021	steiner mitchell shuster	sold	-417,688	20.8844	-20,000	president and ceo
Dec 16, 2020	steiner mitchell shuster	sold	-2,421,620	9.6865	-250,000	president and ceo
Dec 16, 2020	barnette k gary	sold	-1,064,510	10.6451	-100,000	chief scientific officer
Aug 26, 2020	fisch harry	bought	13,799	2.7599	5,000	-
Aug 24, 2020	greco michele	bought	13,233	2.6466	5,000	cao and cfo

Which funds bought or sold VERU recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Charter Oak Capital Management, LLC	new	-	14,002	14,002	-%
Apr 18, 2024	SeaCrest Wealth Management, LLC	new	-	20,303	20,303	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-72.00	-	-%
Apr 16, 2024	180 WEALTH ADVISORS, LLC	new	-	119,542	119,542	0.02%
Apr 16, 2024	Moisand Fitzgerald Tamayo, LLC	sold off	-100	-1,008	-	-%
Apr 16, 2024	Weaver Consulting Group	new	-	15,604	15,604	0.01%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	added	3.33	82.00	17,362	-%
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	-73.00	2,574	-%
Apr 11, 2024	First Affirmative Financial Network	new	-	8,171	8,171	0.01%
Apr 05, 2024	CWM, LLC	unchanged	-	-1,000	-	-%

Are Funds Buying or Selling VERU?

Are funds buying VERU calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VERU

No. of Funds

Unveiling Veru Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	3.8%	5,584,699	SC 13G/A
Feb 06, 2024	frost phillip md et al	3.5%	5,100,253	SC 13G/A
Dec 26, 2023	adage capital partners gp, l.l.c.	9.50%	13,722,222	SC 13G
Dec 08, 2023	morgan stanley	4.2%	3,756,588	SC 13G/A
Sep 28, 2023	frost phillip md et al	5.7%	5,100,253	SC 13G/A
Jun 08, 2023	blackrock inc.	4.98%	4,421,516	SC 13G/A
Apr 19, 2023	frost phillip md et al	6.1%	5,000,253	SC 13G
Feb 14, 2023	perceptive advisors llc	9.7%	7,858,011	SC 13G
Feb 14, 2023	tang capital partners lp	0.0%	0	SC 13G/A
Feb 10, 2023	blackrock inc.	5.8%	4,654,892	SC 13G/A

Recent SEC filings of Veru Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	DEFA14A	DEFA14A
Apr 01, 2024	10-Q	Quarterly Report
Apr 01, 2024	10-K/A	Annual Report
Mar 22, 2024	DEFA14A	DEFA14A
Feb 28, 2024	8-K	Current Report
Feb 15, 2024	NT 10-Q	NT 10-Q
Feb 15, 2024	8-K	Current Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	8-K	Current Report
Feb 06, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Veru Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-12.04%	-45.12%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Veru Inc News

Latest updates

Veru Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-44.6%	2,140,726	3,862,012	3,341,185	6,585,967	2,507,794	2,588,631	9,602,195	13,028,394	14,135,132	15,646,460	17,655,592	13,340,487	14,616,989	11,749,186	10,321,754	9,943,104	10,578,016	8,728,403	9,727,060	6,976,115	6,371,809
Gross Profit	-25.4%	1,150,452	1,541,180	1,230,618	4,092,075	702,055	505,405	7,068,623	11,175,278	11,842,082	12,309,178	13,873,112	10,908,300	10,836,633	9,562,147	6,519,118	7,436,498	7,269,095	5,832,733	6,571,158	4,608,851	4,644,080
Operating Expenses	-25.6%	9,951,481	13,378,886	13,828,087	43,510,841	36,290,214	45,177,941	28,892,398	22,940,242	16,804,367	14,180,404	16,744,976	12,379,710	10,059,634	6,731,918	7,911,970	7,736,176	9,053,488	7,290,308	8,413,160	6,733,441	5,655,807
S&GA Expenses	22.5%	8,301,431	6,774,559	10,902,916	12,834,494	17,545,865	18,290,515	10,761,486	7,401,138	6,723,206	5,924,812	5,556,730	4,806,897	4,381,880	3,463,426	3,475,474	3,805,916	3,753,514	3,685,006	3,547,046	3,822,854	3,293,984
R&D Expenses	-75.0%	1,650,050	6,604,327	2,925,171	22,864,633	18,744,349	26,890,426	18,133,412	15,541,104	10,081,161	8,255,592	11,188,246	7,572,813	5,677,754	3,268,492	4,436,496	3,930,260	5,299,974	3,605,302	4,866,114	2,910,587	2,361,823
EBITDA Margin	29.2%	-3.91	-5.52	-8.00	-6.35	-3.96	-2.01	-0.81	-0.42	-0.23	0.15	0.02	0.07	-	-	-	-	-	-	-	-	-
Interest Expenses	-20.4%	164,957	207,201	648,917	697,693	873,230	812,321	1,185,093	1,212,702	1,158,682	1,157,795	1,287,525	1,251,551	1,189,183	1,145,343	1,169,692	1,164,962	1,141,425	1,078,085	1,091,276	1,258,272	1,278,423
Income Taxes	-113.0%	-72,439	557,492	57,551	-66,559	-68,278	11,589	137,603	-27,450	114,655	-356,067	-2,873,063	21,690	78,302	-1,109,060	240,502	-133,140	-76,743	-421,140	-458	25,167	92,498
Earnings Before Taxes	18.4%	-8,348,420	-10,236,195	-6,602,630	-38,859,465	-36,910,457	-41,011,019	-22,057,973	-14,205,280	-6,265,351	-4,650,547	-5,565,929	-2,824,291	17,306,003	-12,941,605	-2,784,878	-943,649	-3,381,844	-3,481,597	-2,774,534	-4,008,868	-2,056,300
EBT Margin	29.2%	-4.02	-5.68	-8.21	-6.52	-4.12	-2.12	-0.90	-0.51	-0.32	0.07	-0.07	-0.02	-	-	-	-	-	-	-	-	-
Net Income	23.3%	-8,275,981	-10,793,687	-6,660,181	-38,792,906	-36,842,179	-41,022,608	-22,195,576	-14,177,830	-6,380,006	-4,294,480	-2,692,866	-2,845,981	17,227,701	-11,832,545	-3,025,380	-810,509	-3,305,101	-3,060,457	-2,774,076	-4,034,035	-2,148,798
Net Income Margin	29.1%	-4.05	-5.71	-8.21	-6.52	-4.12	-2.13	-0.90	-0.46	-0.27	0.12	0.00	-0.01	-	-	-	-	-	-	-	-	-
Free Cashflow	38.0%	-6,020,389	-9,705,334	-18,457,329	-25,697,258	-34,819,593	-21,027,305	-14,118,848	-4,131,902	-8,960,001	-1,028,701	-12,976,589	-2,594,438	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	59.2%	80,567	50,596	62,221	70,254	103,782	136,126	160,577	172,825	172,165	178,147	180,073	181,151	72,788	51,544	65,188	55,876	54,536	53,629	53,841	51,012	52,335
Current Assets	126.9%	53,345	23,506	34,685	43,288	73,009	104,769	128,361	140,461	145,707	151,753	154,406	156,052	47,567	27,015	26,859	17,460	16,816	16,807	17,143	14,143	15,373
Cash Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,039	5,897	8,979
Inventory	3.2%	6,912	6,697	6,490	7,665	8,733	8,619	7,723	6,415	4,900	5,574	6,946	7,795	6,666	6,704	5,194	6,016	4,595	3,647	3,131	2,998	2,698
Net PPE	-5.6%	1,560	1,653	1,492	1,520	1,426	1,186	1,082	1,025	869	593	392	271	288	313	315	332	336	352	315	321	362
Goodwill	0%	6,879	6,879	6,879	6,900	6,900	6,900	6,879	6,879	6,879	6,879	6,879	6,879	6,879	6,900	6,879	6,879	6,879	6,879	6,879	6,879	6,879
Liabilities	-11.7%	28,965	32,813	40,808	53,538	54,684	55,287	43,710	36,827	24,160	25,853	25,105	25,655	24,040	21,432	23,909	24,762	24,894	21,296	19,105	17,468	15,453
Current Liabilities	-18.0%	16,625	20,279	27,686	39,260	40,080	41,438	27,809	21,181	13,941	15,767	17,212	18,867	17,063	14,727	17,373	16,820	16,909	14,020	11,663	11,272	9,742
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,703
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,703
Shareholder's Equity	190.2%	51,602	17,783	21,413	16,716	49,099	80,839	116,868	135,998	148,004	152,294	154,968	155,496	48,748	30,111	41,279	31,115	29,643	32,333	34,736	33,544	36,882
Retained Earnings	-2.5%	-265,044	-258,663	-247,869	-241,209	-202,416	-165,574	-124,551	-102,356	-88,178	-81,798	-77,503	-74,810	-71,964	-89,192	-77,360	-74,334	-73,524	-70,219	-67,158	-64,384	-60,350
Additional Paid-In Capital	14.0%	323,549	283,895	276,756	265,466	259,075	253,974	248,984	245,920	243,748	241,659	240,040	237,876	128,360	126,972	126,307	113,159	110,883	110,268	109,613	105,667	104,972
Accumulated Depreciation	1.7%	3,854	3,788	-	-	-	3,642	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	59.5%	146,381	91,783	89,237	82,577	80,623	80,509	80,055	80,053	80,023	79,970	79,729	72,718	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	77,700	-	-	-	311,400	-	-	-	689,500	-	-	-	162,300	-	-	-	67,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	36.6%	-6,020	-9,492	-18,431	-25,555	-34,534	-20,878	-14,022	-3,946	-8,657	-806	-12,834	-2,589	659	-341	3,339	-2,416	-2,510	-955	-527	-2,496	-1,506
Share Based Compensation	-27.3%	3,407	4,685	4,551	3,838	4,845	4,326	2,911	2,125	1,880	1,363	1,900	1,002	785	665	685	682	614	524	468	496	417
Cashflow From Investing	-100.0%	-	787	5,974	-141	-285	-148	2,403	-185	2,198	-222	-142	-4.93	14,993	-32.32	-18.76	-32.87	-21.81	-33.57	-74.30	-	-
Cashflow From Financing	1646.0%	36,974	2,118	5,172	2,268	1,556	667	154	43.00	204	232	-542	108,348	1,681	-1,432	9,517	832	412	-755	2,745	-585	6,726

VERU Income Statement

2023-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2023	Sep. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Net revenues	$ 16,296,958	$ 39,354,352
Cost of sales	8,731,030	8,762,964
Gross profit	7,565,928	30,591,388
Operating expenses:
Research and development	51,202,219	70,910,701
Selling, general and administrative	48,057,834	43,177,345
Provision for (recovery of) credit losses	3,911,714	(8,500)
Impairment of intangible assets	3,900,000
Total operating expenses	107,071,767	114,079,546
Gain on sale of ENTADFI® assets	5,723,623
Operating loss	(93,782,216)	(83,488,158)
Non-operating income (expenses):
Interest expense	(2,427,041)	(4,368,798)
Change in fair value of derivative liabilities	2,963,000	3,557,000
Other income, net	573,771	495,735
Total non-operating income (expenses)	1,109,730	(316,063)
Loss before income taxes	(92,672,486)	(83,804,221)
Income tax expense	480,206	236,397
Net loss	$ (93,152,692)	$ (84,040,618)
Net loss per basic common share outstanding	$ (1.10)	$ (1.05)
Basic weighted average common shares outstanding	84,973,382	80,122,526
Net loss per diluted common share outstanding	$ (1.10)	$ (1.05)
Diluted weighted average common shares outstanding	84,973,382	80,122,526

VERU Balance Sheet

2023-09-30

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 9,625,494	$ 80,190,675
Accounts receivable, net	4,506,508	3,550,895
Inventories, net	6,697,117	8,618,944
Prepaid research and development costs	1,006,252	9,677,020
Prepaid expenses and other current assets	1,097,851	1,964,373
Total current assets	22,933,222	104,001,907
Plant and equipment, net	1,652,732	1,185,766
Operating lease right-of-use asset	4,332,473	4,786,915
Deferred income taxes	12,707,419	12,965,985
Intangible assets, net	5,952	3,977,381
Goodwill	6,878,932	6,878,932
Other assets	1,512,361	1,561,564
Total assets	50,023,091	135,358,450
Current liabilities:
Accounts payable	12,931,172	22,003,394
Accrued research and development costs	31,663	6,345,255
Accrued compensation	990,609	5,986,557
Accrued expenses and other current liabilities	1,956,075	2,249,995
Residual royalty agreement, short-term portion (Note 9)	864,623	1,169,095
Operating lease liability, short-term portion	1,036,590	957,085
Total current liabilities	17,810,732	38,711,381
Residual royalty agreement, long-term portion (Note 9)	8,870,136	9,656,441
Operating lease liability, long-term portion	3,634,114	4,093,667
Deferred income taxes		81,067
Other liabilities	29,948	18,577
Total liabilities	30,344,930	52,561,133
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock, no shares issued and outstanding at September 30, 2023 and 2022, respectively
Common stock, par value $0.01 per share; 308,000,000 and 154,000,000 shares authorized, 93,966,402 and 82,692,598 shares issued and 91,782,698 and 80,508,894 shares outstanding at September 30, 2023 and 2022, respectively	939,664	826,926
Additional paid-in-capital	283,894,830	253,974,032
Accumulated other comprehensive loss	(581,519)	(581,519)
Accumulated deficit	(256,768,209)	(163,615,517)
Treasury stock, 2,183,704 shares, at cost	(7,806,605)	(7,806,605)
Total stockholders' equity	19,678,161	82,797,317
Total liabilities and stockholders' equity	$ 50,023,091	$ 135,358,450

About Veru Inc

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

CEO	Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.
WEBSITE	verupharma.com
INDUSTRY	Biotechnology
EMPLOYEES	233

Veru Inc Frequently Asked Questions

What is the ticker symbol for Veru Inc? What does VERU stand for in stocks?

VERU is the stock ticker symbol of Veru Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veru Inc (VERU)?

As of Tue Apr 23 2024, market cap of Veru Inc is 185.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERU stock?

You can check VERU's fair value in chart for subscribers.

What is the fair value of VERU stock?

You can check VERU's fair value in chart for subscribers. The fair value of Veru Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Veru Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Veru Inc a good stock to buy?

The fair value guage provides a quick view whether VERU is over valued or under valued. Whether Veru Inc is cheap or expensive depends on the assumptions which impact Veru Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERU.

What is Veru Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, VERU's PE ratio (Price to Earnings) is -2.88 and Price to Sales (PS) ratio is 11.67. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERU PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veru Inc's stock?

In the past 10 years, Veru Inc has provided -0.164 (multiply by 100 for percentage) rate of return.